PMID: 9551367Apr 29, 1998Paper

Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro

Journal of Immunotherapy
T TjandrawanW J Storkus

Abstract

The recent identification of tumor-associated antigens and tumor-associated antigen-derived peptide epitopes recognized by cytolytic T lymphocytes (CTLs) in the context of major histocompatibility complex (MHC) class I molecules has prompted the development of peptide-based vaccines for the treatment of human cancers, particularly melanoma. The design of such clinical protocols requires an understanding of the inherent immunogenicity of the peptide(s) and a choice of a facilitating adjuvant promoting cellular immunity against these peptides. We have evaluated the abilities of a series of defined synthetic peptide epitopes derived from MART-1/Melan-A, gp100, tyrosinase, and MAGE-3 or unfractionated peptides naturally presented by melanoma MHC molecules to elicit HLA-A2-restricted and melanoma-reactive CTLs from the peripheral blood of normal donors or patients with metastatic melanoma. Autologous peripheral blood dendritic cells (DCs), which were easily generated from all donors when cultured in the presence of recombinant human interleukin-4 and recombinant human granulocyte-macrophage colony-stimulating factor were pulsed with melanoma peptides and used to "prime" and/or "boost" CTL cultures in vitro. Our results suggest that ...Continue Reading

Citations

Aug 24, 1999·Medical Oncology·P JantscheffC Rochlitz
Aug 8, 2002·Journal of Immunological Methods·Vinod PullarkatJeffrey S Weber
Apr 29, 2000·Current Opinion in Hematology·T L Warren, G J Weiner
Feb 28, 2002·Annual Review of Immunology·Pierre GuermonprezSebastian Amigorena
Jan 9, 2003·Expert Opinion on Biological Therapy·Tomohide Tatsumi, Walter J Storkus
Oct 26, 1999·Immunobiology·M Zöller, S Matzku
Sep 23, 2003·Clinical Breast Cancer·Lawrence G LumGerald J Elfenbein
Dec 21, 2004·International Journal of Cancer. Journal International Du Cancer·Sebastian OerkeMarkus J Maeurer
Aug 14, 1999·Scandinavian Journal of Immunology·M MaeurerU Seitzer
Nov 10, 2004·Journal of Immunotherapy·Lee W ThompsonCraig L Slingluff
Apr 13, 2005·International Journal of Cancer. Journal International Du Cancer·Kouji TanakaHiroyuki Honda
Jul 28, 2020·European Journal of Immunology·Lucy C WaltersGeraldine M Gillespie
Jun 11, 1999·International Journal of Cancer. Journal International Du Cancer·E JägerM J Maeurer
Dec 22, 1999·The Journal of Immunology : Official Journal of the American Association of Immunologists·X DongR D Salter
Apr 30, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Timothy L FrankelRichard A Morgan
Mar 7, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Rossella SartoriusPiergiuseppe De Berardinis
Jul 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E KeoghA Sette
Oct 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·B CochloviusM Zöller
Dec 16, 1998·Journal of Virology·I V Redchenko, A B Rickinson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.